Skip to Content

Join the 'Zepatier' group to help and get support from people like you.

Zepatier News

Could a Monetary Perk Help Keep HIV Patients on Their Meds?

Posted 22 Jun 2017 by

WEDNESDAY, June 21, 2017 – There are mixed results from a new study on the use of monetary rewards to help boost the odds that HIV-infected patients will enter care, and take their meds as directed. The study, conducted at HIV clinics in New York City and Washington, D.C., found that financial incentives such as gift cards could improve the likelihood that HIV patients would take antiretroviral ...

Americans With HIV Staying on Lifesaving Meds Longer

Posted 31 May 2017 by

WEDNESDAY, May 31, 2017 – More Americans with HIV are sticking with medications that turn a fatal disease into a manageable condition, a new study shows. "This represents a lot of people who are not dying and not infecting others," said study corresponding author Ira Wilson, chair of Brown University's Health Services Policy and Practice Department, in Providence, R.I. "These differences ...

New Hepatitis C Treatments More Effective, Tolerable: FDA

Posted 11 May 2017 by

THURSDAY, May 11, 2017 – Hepatitis C can be cured in about three months, allowing people with the viral disease to live longer, healthier lives, the U.S. Food and Drug Administration (FDA) says. Drugs used to clear the virus from the body are not only more effective than they once were but also more tolerable for patients, according to Dr. Jeffrey Murray, an internist at the FDA who specializes ...

Doctors Seeing More HIV Patients With Multidrug Resistance

Posted 1 Dec 2016 by

THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked ...

FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

Posted 10 Oct 2016 by

ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually ...

HIV Infection Seems to Affect Nervous System

Posted 13 Jun 2016 by

MONDAY, June 13, 2016 – Many newly infected HIV patients experience neurological problems, but they tend to be mild and they subside after antiretroviral drugs are given, a new study finds. "We were surprised that neurologic findings were so pervasive in participants diagnosed with very recent HIV infection," said study author Dr. Joanna Hellmuth. She is a clinical fellow in the department of ...

HIV Decline Falls Short of U.S. 5-Year Goal

Posted 6 May 2016 by

FRIDAY, May 6, 2016 – Although HIV infection and transmission rates in the United States declined over the past five years, they fell short of White House targets, a new study finds. Between 2010 and 2015, new HIV infections decreased 11 percent and transmission of the AIDS-causing virus declined 17 percent, far less than the goals set in 2010 as part of the U.S. National HIV/AIDS Strategy ...

Zepatier Approved for Chronic Hepatitis C

Posted 3 Feb 2016 by

FRIDAY, Jan. 29, 2016 – Zepatier (a combination of elbasavir and grazoprevir) has been approved by the U.S. Food and Drug Administration to treat chronic infection with the hepatitis C virus, genotypes 1 and 4. Hepatitis C causes liver inflammation, which can lead to liver failure. Most infected people have no symptoms until the onset of liver damage, which could take several years, the FDA said ...

FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4

Posted 29 Jan 2016 by

January 28, 2016 – The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with HCV ...

Ask a Question

Further Information

Related Condition Support Groups

Hepatitis C

Zepatier Patient Information at